Nuvation Bio (NUVB) Accumulated Depreciation (2020 - 2025)

Nuvation Bio (NUVB) has reported Accumulated Depreciation for 6 consecutive years, with $1.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Accumulated Depreciation rose 35.47% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $1.2 million (up 35.47% YoY), while the FY2025 annual figure was $1.2 million, up 35.47% from the prior year.
• Accumulated Depreciation rose to $1.2 million in Q4 2025 per NUVB's latest filing, from $874000.0 in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $1.2 million in Q4 2025 and bottomed at $291000.0 in Q4 2021.
• Historically, Accumulated Depreciation has averaged $694600.0 across 5 years, with a median of $666000.0 in 2023.
• Annual changes were most pronounced in 2021 — Accumulated Depreciation soared 150.86% — and 2024, when it surged 31.23%.
• Nuvation Bio's Accumulated Depreciation stood at $291000.0 in 2021, then soared by 57.39% to $458000.0 in 2022, then surged by 45.41% to $666000.0 in 2023, then soared by 31.23% to $874000.0 in 2024, then jumped by 35.47% to $1.2 million in 2025.
• Business Quant data shows NUVB's Accumulated Depreciation at $1.2 million in Q4 2025, $874000.0 in Q4 2024, and $666000.0 in Q4 2023.